Day: March 6, 2024

Inside information: SATO Corporation announces results regarding tender offer of outstanding notes due 2028

Written by Customer Service on March 6, 2024. Posted in Mergers And Acquisitions.

SATO Corporation, Stock Exchange Release 6 March 2024 at 10:00 am SATO Corporation has today announced the results of its invitation to holders of its outstanding EUR 350,000,000 1.375 per cent notes due 24 February 2028 to tender such notes for cash up to an aggregate principal amount of EUR 50 million. The results are as follows: ISIN: XS2233121792 Maturity date: 24 February 2028 Issued amount (EUR): 350,000,000 Repurchased amount (EUR): 50,000,000 The expected Settlement Date in respect of the Tender Offer is 8 March 2024. Full details concerning the Tender Offer are set out in the Tender Offer Memorandum. For more information, please contact: Markku Honkasalo, CFO, phone: +358 201 134 4226 Henry Lindqvist, Group Treasurer, phone +358 50 317 2352 www.sato.fi/en SATO Corporation is an expert...

Vow ASA: Contract wins in heat intensive sector

Written by Customer Service on March 6, 2024. Posted in Public Companies.

Oslo/Fredrikstad, 6 March 2024: Vow ASA (OSE: VOW) subsidiary C.H. Evensen continues to prove its relevance in the heat intensive industry sector, this by being awarded NOK 30 million of contracts to undisclosed blue chip recurring customers in Europe. The bidding activity continues to be high in Vow’s Heat Solutions division, and the order backlog within this division now stands at around NOK 110 million of which a substantial part will convert to revenue in 2024 with robust margins. Faced with high costs for energy and emissions, companies in heat intensive industries are intensifying their efforts to decarbonise. Electrification of heating processes is becoming increasingly relevant and therefore popular. For C.H. Evensen this has meant more than doubled revenue in two years, from NOK 59 million in 2021 to NOK 121 million in 2023.For...

LIFT intersects 19 m at 1.31% Li2O at its Fi Southwest pegmatite & 23 m at 1.03% Li2O at its Echo pegmatite, Yellowknife Lithium Project, NWT

Written by Customer Service on March 6, 2024. Posted in Public Companies.

Figure 1Location of LIFT’s Yellowknife Lithium Project. Drilling has been thus far focused on the Near Field Group of pegmatites which are located to the east of the city of Yellowknife along a government-maintained paved highway, as well as the Echo target in the Further Afield Group.Figure 2Plan view showing the surface expression of the Fi Southwest pegmatite with diamond drill hole reported in this press release.Figure 3Cross-section illustrating YLP-0200 with results as shown in the Fi Southwest pegmatite dyke with a 19 m interval of 1.31% Li2O.Figure 4Plan view showing the surface expression of the Echo pegmatite with diamond drill holes reported in this press release.Figure 5Cross-section of YLP-0203 which intersected the Echo pegmatite dyke with a 13 m interval of 1.24% Li2O.Figure...

Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function

Written by Customer Service on March 6, 2024. Posted in Public Companies.

Three Clinical Data Sets from the Dose Escalation Phase of COVALENT-111 to be Presented at the 17th Annual ATTD Conference Highlighting BMF-219’s Novel Mechanism of Action in Patients with Type 2 DiabetesPatients in COVALENT-111 are displaying improved glycemic control while off therapy out to Week 26 following the 28-day treatment with BMF-219, supporting enhanced pancreatic islet function as the mechanism of action BMF-219 was generally well tolerated with no serious adverse events and no adverse event-related study discontinuations, and no symptomatic or clinically significant hypoglycemia 100mg and 200mg dose levels have been selected for the first 3 Arms of the Expansion Phase, which will dose patients up to 12 weeks (compared to 4 weeks in the Escalation Phase) and extended follow-up to Week 52 The Expansion Phase of COVALENT-111...

Form 8.5 (EPT/RI) – Renalytix plc

Written by Customer Service on March 6, 2024. Posted in Public Companies.

FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Name of exempt principal trader: Investec Bank plc(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Renalytix plc(c) Name of the party to the offer with which exempt principal trader is connected: Investec is Joint Broker to Renalytix plc(d) Date dealing undertaken:5th March 2024(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer? If it is a cash offer or possible cash offer, state...

Sampo issues outlook statement for 2024

Written by Customer Service on March 6, 2024. Posted in Public Companies.

SAMPO PLC STOCK EXCHANGE RELEASE 6 March 2024 at 9:30 amSampo issues outlook statement for 2024 Sampo Group has this morning announced new financial targets for the 2024–2026 strategic period. Subsequently, the Group is issuing a first outlook statement for 2024. Sampo Group is expected to deliver a combined ratio in 2024 that meets the 2024-2026 annual target of below 85 per cent, including an assumed discount rate benefit of 2 percentage points. SAMPO PLC Board of Directors For further information, please contact: Sami TaipalusHead of Investor Relationstel. +358 10 516 0030 Distribution: Nasdaq Helsinki Nasdaq Stockholm London Stock Exchange FIN-FSA The principal media www.sampo.com

VALNEVA Declaration of shares and voting rights – February 29, 2024

Written by Customer Service on March 6, 2024. Posted in Public Companies.

VALNEVA Declaration of shares and voting rights February 29, 2024__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris – Compartment B Declaration date: March 6, 2024Number of shares composing the share capital of Valneva Total number of voting rights including suspended voting rights* Description of the change Date on which this change was recognized Total number of voting rights excluding suspended voting rights** 138,912,142 ordinary shares with a par value of €0.15 each 160,870,300 Double voting rights granted on 3,843 ordinary shares Transfer into bearer form of 1,000,000 shares with double voting rights Between February 1 &...

Dassault Aviation: Availability of a short form of the 2023 Annual Financial Report

Written by Customer Service on March 6, 2024. Posted in Public Companies.

Availability of a short formof the 2023 Annual Financial Report A short form of the Dassault Aviation 2023 Annual Financial Report (version abrégée du Rapport Financier Annuel 2023) is available to the public, awaiting the issuance of the statutory auditors’ reports. This short form of the 2023 Annual Financial Report can be found on the company’s website at www.dassault-aviation.com, in the “Finance / Publications / 2024 Publications” section. The full 2023 Annual Financial Report will be made available to the public and filed with the French Financial Markets Authority (Autorité des Marchés Financiers) later in March 2024. ABOUT DASSAULT AVIATION: With over 10,000 military and civil aircraft (including 2,500 Falcons) delivered in more than 90 countries over the last century, Dassault Aviation has built up expertise recognized...

Dassault Aviation: 2023 Annual Results Financial Release

Written by Customer Service on March 6, 2024. Posted in Earnings Releases And Operating Results.

KEY FIGURES OF DASSAULT AVIATION GROUP 2023 2022Order intake EUR 8,253 million 60 Rafale of which 42 France and 18 Export 23 Falcon EUR 20,954 million 92 Rafaleof which 92 Export 64 FalconAdjusted net sales (*) EUR 4,801 million 13 Rafale of which 11 France and 2 Export 26 Falcon EUR 6,929 million 14 Rafale of which 13 Export and 1 France 32 FalconBacklog as of December 31 EUR 38,508 million 211 Rafale of which 141 Export and 70 France 84 Falcon EUR 35,008 million 164 Rafale of which 125 Export and 39 France 87 FalconAdjusted operating income(*) Adjusted operating margin EUR 349 million 7.3% of net sales EUR 572 million 8.3% of net salesSelf-funded Research and Development EUR 483 million 10.1% of net sales EUR 572 million 8.3% of net salesAdjusted net income (*) Adjusted net margin Earnings per share EUR 886 million 18.5%...

Virbac to take a leading position in Japan through the acquisition of Sasaeah

Written by Customer Service on March 6, 2024. Posted in Mergers And Acquisitions.

Virbac announces that it has signed a definitive agreement with ORIX Corporation for the acquisition of its animal health subsidiary Sasaeah for an enterprise value of approximately €280 million. Formed through the combination of two legacy animal health providers (Fujita Pharmaceutical Co. Ltd. and Kyoto Biken Laboratories Inc.) under the stewardship of ORIX Corporation, Sasaeah generates annual revenues of about €75 million, of which 50% from vaccines. With strong footholds in Japan, Sasaeah develops, manufactures and markets a large portfolio of veterinary products targeting both farm animals and companion animals. Upon completion, this strategic acquisition will bring to Virbac a leadership position in the farm animal vaccines market in Japan, notably in the cattle segment, and a large portfolio of pharmaceutical products...

Day: March 6, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice